A Preliminary Study of D-Cycloserine Augmentation of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive Disorder

Storch, Eric A.; Murphy, Tanya K.; Goodman, Wayne K.; Geffken, Gary R.; Lewin, Adam B.; Henin, Aude; Micco, Jamie A.; Sprich, Susan E.; Wilhelm, Sabine; Bengtson, Michael A.; Geller, Daniel

doi:10.1016/j.biopsych.2010.07.015

Cited by 170 publications

(140 citation statements)

References 18 publications

Supporting

Mentioning

132

Contrasting

Unclassified

Order By: Relevance

“…However the value of combination treatment over psychological or pharmacological treatments given alone over the long term is uncertain. A series of small randomised placebo-controlled studies suggest that administration of d-cycloserine may hasten the response to CBT, but provide no evidence that the overall effectiveness of CBT is enhanced [I (PCT)] (Kushner et al, 2007;Storch et al, 2010;Wilhelm et al, 2008).…”

Section: Comparative Efficacy Of Pharmacological Psychological and Cmentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and clinical management, including recognition, acute treatment, longer-term treatment, combination treatment, and further approaches for patients who have not responded to first-line interventions. A consensus meeting involving international experts in anxiety disorders reviewed the main subject areas and considered the strength of supporting evidence and its clinical implications. The guidelines are based on available evidence, were constructed after extensive feedback from participants, and are presented as recommendations to aid clinical decision-making in primary, secondary and tertiary medical care. They may also serve as a source of information for patients, their carers, and medicines management and formulary committees.

show abstract

Section: Comparative Efficacy Of Pharmacological Psychological and Cmentioning

confidence: 99%

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

et al. 2014

View full text Add to dashboard Cite

show abstract

“…As the mechanism of CBT for OCD is to extinguish the relationship between an anxiety-producing stimulus and obsessive fear by exposing patients to these stimuli, one could potentially enhance this extinction by taking D-cycloserine approximately 1 h before CBT sessions. Two RCTs have confirmed that D-cycloserine has an additive effect when combined with CBT, as it was proven to be superior to CBT+pill placebo [85,86]. In line with this synthesized theory, D-cycloserine does not seem to work when administered after E/RP sessions [87].…”

Section: D-cycloserine and Cbtmentioning

confidence: 53%

Evidence-Based Treatments in Treatment-Naïve and Treatment-Resistant Pediatric Obsessive-Compulsive Disorder

Skarphéðinsson

Ivarsson

2015

Curr Behav Neurosci Rep

View full text Add to dashboard Cite

Pediatric obsessive-compulsive disorder (OCD) is a chronic, disabling, and common disorder. In this paper, we describe evidence-based treatments in treatment-naïve and treatment-refractory pediatric OCD patients. We conducted a PubMed search to identify randomized controlled trials, reviews, and expert guidelines. The evidence for cognitive behavior therapy (CBT) and specific serotonin reuptake inhibitors (SSRIs) among treatment-naïve patients is substantial and shows that both treatments are effective. Head-to-head trials in pediatric OCD only show that CBT is significantly more effective than SSRI. The evidence among CBT and SSRI non-responders is limited. One trial among CBT non-responders showed that both continued CBT and switching to an SSRI are effective strategies. Likewise, one trial among SSRI non-responders showed that augmenting with CBT is necessary. Evidence of treatments for treatment-refractory pediatric OCD is lacking. We describe the treatments available and evidence from studies of adult OCD. Evidence for emerging treatments such as modifying CBT and glutamatergic drugs is also described.

show abstract

“…Similarly, one study demonstrated no positive effect of systemic pre-extinction DCS on ethanol-CPP extinction acquisition, although it did report an enhanced persistence of extinction during reconditioning (Groblewski et al, 2009). Moreover, recent studies in humans have also revealed that DCS administered before extinction had no effects on the extinction of drug dependence (Price et al, 2012;Watson et al, 2011) and on a variety of behavioral disorders (Guastella, Lovibond, Dadds, Mitchell, & Richardson, 2007;Storch et al, 2010). It has also been shown that pre-extinction DCS administration facilitated fear extinction, although extinguished fear was normally renewed, suggesting that the drug may modestly facilitate extinction learning, but does not destroy the potential for relapse (Woods & Bouton, 2006).…”

Section: Discussionmentioning

confidence: 99%

d-cycloserine in the basolateral amygdala prevents extinction and enhances reconsolidation of odor-reward associative learning in rats

Portero-Tresserra

Martí-Nicolovius

Guillazo-Blanch

et al. 2013

Neurobiology of Learning and Memory

View full text Add to dashboard Cite

It is well established that D-cycloserine (DCS), a partial agonist of the NMDA receptor glycine site, enhances learning and memory processes. Although the effects of DCS have been especially elucidated in the extinction and reconsolidation of aversive behavioral paradigms or drug-related behaviors, they have not been clearly determined in appetitive tasks using natural reinforcers. The current study examined the effects of pre-retrieval intra-basolateral amygdala (BLA) infusions of DCS on the extinction and reconsolidation of an appetitive odor discrimination task. Rats were trained to discriminate between three odors, one of which was associated with a palatable food reward and, twenty minutes prior to extinction learning (experiment 1) or reactivation (experiment 2), they received bilateral intra-BLA infusions of DCS or vehicle. In experiment 1, DCS infusion reduced the rate of extinction learning acquisition, weakened extinction retention in a post-extinction test and enhanced reacquisition of the ODT task. In experiment 2, DCS improved subsequent memory expression in the reconsolidation test performed one day after the reactivation session. Such results indicate the involvement of BLA NMDA receptors in odor-food reward associative memory and suggest that DCS may potentiate the persistence or strength of the original memory trace.

show abstract

A Preliminary Study of D-Cycloserine Augmentation of Cognitive-Behavioral Therapy in Pediatric Obsessive-Compulsive Disorder

Cited by 170 publications

References 18 publications

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

Evidence-Based Treatments in Treatment-Naïve and Treatment-Resistant Pediatric Obsessive-Compulsive Disorder

d-cycloserine in the basolateral amygdala prevents extinction and enhances reconsolidation of odor-reward associative learning in rats

Contact Info

Product

Resources

About